alxn1840
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jan 20, 2014 (NCT05319899)
Timeline
Indications
Mechanism of action
- CopperCHELATING AGENT
Copper chelating agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- wtx101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05047523 | Phase 3 | Oct 6, 2021 | Alexion |
| NCT04610580 | Phase 1 | Dec 31, 2020 | Alexion |
| NCT04573309 | Phase 2 | Sep 7, 2020 | Alexion |
| NCT04526210 | Phase 1 | Aug 31, 2020 | Alexion |
| NCT04560816 | Phase 1 | Jul 24, 2020 | Alexion, ERT Clinical, PPD |
| NCT04526197 | Phase 1 | Jul 8, 2020 | Alexion |
| NCT04594252 | Phase 1 | Jul 1, 2020 | Alexion |
| NCT05303324 | Phase 1 | Jul 4, 2019 | Alexion |
| NCT05641311 | Phase 1 | Feb 20, 2019 | Alexion |
| NCT03403205 | Phase 3 | Feb 15, 2018 | Alexion, Wilson Therapeutics AB |
| NCT02273596 | Phase 2 | Nov 1, 2014 | Wilson Therapeutics AB |
| NCT05319899 | Phase 1 | Jan 20, 2014 | Alexion |
| NCT05686564 | N/A | — | Alexion |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 12 | 11 | 4 | 2014 |
| Wilson Therapeutics AB | For profit | 2 | 2 | 2 | 2014 |
| ERT Clinical | For profit | 1 | 0 | 1 | 2020 |
| PPD | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1